Sylvia Shoffner, MD
Internal Medicine · Cary, NCNPI 1912049669
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.4%), food and beverage and gifts — rather than concentrated in one kind of arrangement. Boehringer Ingelheim International GmbH accounts for 76.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $1,593 and has fallen 95.2% since, to $76 in 2025.
Across 34 payments — averaging $55.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Abbott$113
- Astellas Pharma US Inc$55
- AbbVie$48
- Pfizer$45
- Novo Nordisk$24
- plus $152 from 9 others
Across 740 payments — averaging $9548.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2.4M
- Bavarian Nordic A/s$1.5M
- Johnson & Johnson$851K
- GSK$639K
- Boehringer Ingelheim$554K
- Hoffmann-la Roche Limited$313K
- plus $748K from 11 others
What the payments were for
- Travel & lodging$94350%
- Food & beverage$89348%
- Education$151%
- Gifts$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,433 |
| Abbott | 5 | $113 |
| Astellas Pharma US Inc | 3 | $55 |
| AbbVie | 2 | $48 |
| Pfizer | 3 | $45 |
| Novo Nordisk | 1 | $24 |
| Exact Sciences | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amgen | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$1,871 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $127,281 |
| JanuviaSitagliptin Phosphate | 59 | $55,479 |
| EliquisApixaban | 39 | $41,719 |
| JardianceEmpagliflozin | 33 | $38,308 |
| MyrbetriqMirabegron | 31 | $27,728 |
| FarxigaDapagliflozin Propanediol | 23 | $22,121 |
| XareltoRivaroxaban | 22 | $19,597 |
| WegovySemaglutide | 11 | $15,071 |
| SynthroidLevothyroxine Sodium | 117 | $8,663 |
| ConcertaMethylphenidate Hcl | 11 | $8,583 |
| BystolicNebivolol Hcl | 15 | $8,186 |
| LinzessLinaclotide | 11 | $6,636 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,959 |
| Estradiol | 38 | $4,338 |
| Levothyroxine Sodium | 366 | $4,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy | $24 | $142,352120 claims |
| PfizerEliquis | $45 | $41,71939 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $27,72831 claims |
| AbbVieSynthroid, Linzess | $48 | $15,300128 claims |
| Kowa Pharmaceuticals America, Inc.Bystolic | $13 | $8,18615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Cary
- Jennings DawkinsCary$109K
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.